Nathan Gaul
Research Triangle Park Foundation(US)GlaxoSmithKline (United States)(US)
Research Areas
Autophagy in Disease and Therapy, Endoplasmic Reticulum Stress and Disease, Cancer, Hypoxia, and Metabolism, Metabolomics and Mass Spectrometry Studies, Pancreatic function and diabetes
Most-Cited Works
- → Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity(2013)426 cited
- → Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development(2013)226 cited
- → Abstract 5418: Rapid LDH5 inhibition reverses malignant metabolic phenotype and impairs survival of hepatocellular carcinoma cells .(2013)2 cited